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Abstract
Background: MicroRNAs [miRNAs] are cell-specific small non-coding RNAs that can regulate gene 
expression and have been implicated in inflammatory bowel disease [IBD] pathogenesis. Here we 
define the cell-specific miRNA profiles and investigate its biomarker potential in IBD.
Methods: In a two-stage prospective multi-centre case control study, next generation sequencing 
was performed on a discovery cohort of immunomagnetically separated leukocytes from 
32 patients (nine Crohn’s disease [CD], 14 ulcerative colitis [UC], eight healthy controls) and 
differentially expressed signals were validated in whole blood in 294 patients [97 UC, 98 CD, 98 
non-IBD, 1 IBDU] using quantitative PCR. Correlations were analysed with phenotype, including 
need for early treatment escalation as a marker of progressive disease using Cox proportional 
hazards.
Results: In stage 1, each leukocyte subset [CD4+ and CD8+ T-cells and CD14+ monocytes] was analysed 
in IBD and controls. Three specific miRNAs differentiated IBD from controls in CD4+ T-cells, including 
miR-1307-3p [p = 0.01], miR-3615 [p = 0.02] and miR-4792 [p = 0.01]. In the extension cohort, in stage 
2, miR-1307-3p was able to predict disease progression in IBD (hazard ratio [HR] 1.98, interquartile 
range [IQR]: 1.20–3.27; logrank p = 1.80 × 10–3), in particular CD [HR 2.81; IQR: 1.11–3.53, p = 6.50 × 10–
4]. Using blood-based multimarker miRNA models, the estimated chance of escalation in CD was 
83% if two or more criteria were met and 90% for UC if three or more criteria are met.
Interpretation: We have identified and validated unique CD4+ T-cell miRNAs that are differentially 
regulated in IBD. These miRNAs may be able to predict treatment escalation and have the potential 
for clinical translation; further prospective evaluation is now indicated.
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1.  Introduction
Inflammatory bowel disease [IBD] is a global health burden with 
increasing incidence and prevalence in newly industrialized nations, 
with healthcare costs in the UK and Europe.1,2 Despite tremendous 
progress in our understanding of the genetics in IBD, there remains a 
large proportion of disease variance that is unexplained. Studies are 
beginning to explore the epigenome as the next tier of information in 
complex immune-mediated diseases.3–5 First implicated in 1993 in epi-
genetic regulation, microRNAs [miRNAs] have now been discovered 
in most species and within most body fluids in humans. MicroRNAs 
are non-coding RNAs that have the ability to regulate and fine-tune 
gene expression. There is strong evidence that IBD pathways are regu-
lated by miRNAs, notably regulation of the Th-17 pathway by the 
NOD2-driven miR-29.6 miR-196 regulates IRGM, which is a known 
IBD GWAS susceptibility gene; the known single nucleotide poly-
morphism [SNP] alters the binding site for miR-196, dysregulating 
xenophagy in Crohn’s disease [CD].7 Most recently, in a detailed 
genome-wide analysis of the disease-associated methylome, our group 
has shown differential hypo-methylation at the transcriptional start 
site for miR-21 and increased expression of pri-miR-21 in leukocytes 
and in inflamed intestinal tissue.4 This miRNA has now been shown 
to have protective effects in miR-21-knockout [KO] mice exposed to 
dextran sodium sulphate [DSS] and deleterious effects when exposed to 
2,4,6-trinitrobenzenesulfonic acid [TNBS].8
There are a number of methodological considerations that po-
tentially confound miRNA analysis, both biological and technical; a 
key issue is cellular heterogeneity. Every cell type possesses its own 
unique epigenetic signature. Therefore, interpreting the relevance of 
miRNAs detected in heterogeneous samples [e.g. whole blood, intes-
tinal biopsies] is challenging.5 Applying next-generation sequencing 
to immune cell subsets provides hypothesis-free and cell-specific pro-
filing of miRNAs. In this study, we have applied sequencing to gen-
erate unique circulating cell-specific signatures in IBD at diagnosis. 
In a multi-centre independent replication cohort, we further assess 
this signal as a biomarker in whole blood and characterize its ac-
curacy in defining disease course. These miRNA models are then in-
corporated into prognostic models with conventional blood markers 
with the ability to accurately predict treatment escalation over time.
2.  Materials and Methods
2.1.  Study design
We conducted a prospective two-stage discovery and validation 
multi-centre case-control study as summarized in Figure 1. Patients 
with a new diagnosis of IBD were included in the study. All IBD cases 
met the standard diagnostic criteria for ulcerative colitis [UC], CD 
or inflammatory bowel disease unclassified [IBDU] following thor-
ough clinical, microbiological, endoscopic, histological and radio-
logical evaluation. The Lennard-Jones, Montreal and Paris criteria 
were used for diagnosis and classification of clinical phenotypes.9–11
2.2.  Stage 1: Discovery cohort
For the discovery cohort, immune-magnetic cell separation was per-
formed using a previously described protocol.12 In brief, peripheral 
blood mononuclear cells were isolated from 18–36  mL of EDTA 
whole blood using Ficoll [Ficoll-Paque, GE Healthcare]. Cells la-
belled with antibody-coated microbeads [human CD14+, CD8+ and 
CD4+ microbeads, 20  µL per 107 cells] were immunomagnetically 
separated using the autoMACs Pro cell separator [Miltenyi] and 
cell purity was estimated using fluorescent antibody staining and 
flow cytometry [FACS Aria II, BD]. Flow cytometric assessment 
demonstrated high purity of isolated cell populations following 
immunomagnetic cell separation (CD14+ median: 92.4% [interquar-
tile range {IQR} 87–94.9], CD4+: 97.3% [93.8–98.9], CD8+: 88.7 
[80.5–93]).
A total of 90 leukocyte subset [CD4+, CD8+ and CD14+ cells] 
samples were obtained from 32 patients [nine CD, 14 UC, one IBDU, 
eight healthy controls] with newly diagnosed IBD, who were naïve to 
therapy, and age- and sex-matched healthy individuals. Demographic 
and clinical data including drug therapies were collected [Table 1A]. 
Cell sample RNA was extracted using the Qiagen Allprep DNA/
RNA miRNA universal kit as per the manufacturer’s instructions. 
The Agilent Bioanalyzer platform and NanoChip kit were used for 
sizing, quantification and quality control [QC] of extracted miRNA 
from separated cells. All separated cells reached high-quality RNA 
integrity number [RIN] [mean RIN 9.2].
Libraries were prepared for 90 separated cell samples using the 
Trilink Clean Tag method. Library preparation involved ligating 
adenylated single strand DNA to the 3′ and 5′ ends of the RNA. 
RNA was then reverse transcribed into cDNA clones and PCR was 
used to amplify sequences, with the addition of barcodes to allow 
pooling of samples. The PCR products were size selected using gel 
electrophoresis to obtain small RNA libraries. Sequencing was per-
formed using the Illumina NovaSeq platform.
2.3.  Stage 2: Validation cohort
Whole blood miRNA for the replication cohort was collected using 
a standardized protocol across UK [Edinburgh] and European 
centres [Sweden, Norway, Spain, Netherlands] in Paxgene tubes and 
stored at −80°C. Total RNA was extracted from whole blood using 
a MagMax extraction kit according to the manufacturer’s instruc-
tions. The validation cohort comprised 294 patients with suspected 
or confirmed IBD and a control group consisting of patients with 
gastrointestinal symptoms [symptomatic controls] who had no dis-
cernible clinical or pathological evidence of IBD at any time during 
follow-up, and healthy controls. Patients were recruited at presen-
tation to gastrointestinal clinics across six clinical centres in the UK 
and Europe as part of the EU Character study [EU Character ref-
erence no. 305676]. Demographic and clinical data including drug 
therapies were collected [Table 1B]. Paired high-sensitivity C-reactive 
protein [hsCRP] and albumin were available in a subcohort of pa-
tients assayed as part of the IBD Character Consortium. Other rou-
tine markers including haemoglobin, white cell count and platelets 
were tested as part of clinical care. Clinical outcome data were col-
lected at follow up for patients with IBD. A total of 73% of patients 
with IBD were naïve to medical therapies in the validation cohort.
A total of seven endogenous controls were identified from a 
literature review as potential controls in whole blood PCR experi-
ments: miR-130b-3p, miR-130b-5p, miR-342-3p, U6, SNORD44, 
SNORD48 and SNORD49A. Controls were tested for their per-
formance and stability across all samples and a GeNorm score was 
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given to each marker. GeNorm calculates stability based on pairwise 
variation and generates a stability score, a lower score representing 
higher stability.13 miR-130b-5p [GeNorm 0.82] and miR-342-3p 
[GeNorm 0.8] had the lowest GeNorm score and were selected for 
further analyses.
miRCURY LNA miRNA PCR assays were designed and 
synthesized by Qiagen for the following mature miRNAs: miR-
130b-3p, miR-130b-5p, miR-200b-3p, miR-342-3p, U6, miR-
1307-3p, SNORD44, SNORD48 and SNORD49A. TaqMan 
Advanced miRNA assays were designed and synthesized by 
ThermoFisher for the following mature miRNAs: miR-3615, miR-
4792, miR-130b-3p, miR-342-3p and miR-130b-5p.
Reverse transcription [RT] of miRNA templates was performed 
according to the manufacturer’s protocol. In brief, 10 ng of RNA 
was polyadenylated and reverse transcribed into cDNA con-
taining UniSp6 [Qiagen] spike-in using the miRCURY LNA RT Kit 
[Qiagen] and cel-miR-39 spike-in for the Taqman cDNA kit on a 
T100 thermal cycler [Bio-Rad]. Real-time qPCRs were performed 
with miRCURY LNA miRNA PCR assays and a miRCURY LNA 
SYBR Green PCR Kit [Qiagen] in a 384-well plate [HardShell 384-
well PCR plates, Bio-Rad] on a QuantStudio 7 Flex Real-Time PCR 
System [ThermoFisher].
2.4.  Clinical outcome data
In the IBD cohort, clinical outcome data were collected over time 
across all centres [Table 2]. Treatment escalation was defined as the 
need for two or more immunomodulators and/or surgery over time 
after initial disease remission.14,15 Treatment naivety within the IBD 
cohorts was defined as no exposure to any IBD-related medical ther-
apies such as oral or topical steroids, 5-aminosalicylic acid [5-ASA] 
therapies, biologics and immunosuppressants.
2.5.  Gene expression profiling
Whole blood RNA underwent targeted RNA sequencing which was 
performed using an Ion AmpliSeq Human Gene Expression Core 
Panel, containing 20 802 genes. QC was performed using the Ion 
Library Taqman Quantitation kit. Sequence reads were aligned using 
the Torrent Suite Software [TSS] and the number of matches per 
amplicon was quantified. After filtering, 14  182 transcripts were 
available for further analysis.
2.6.  Ethics statement
All centres were granted local ethics approval for this study and all 
patients gave written and informed consent prior to participating in 
this study. The study was funded by Crohn’s and Colitis UK [grant 
number M2016/2].
3.  Data Analysis
3.1.  Stage 1: RNA sequencing
Raw reads were aligned to the human genome using miRDeep 2, 
with output restricted to those that aligned full length and were 
Discovery cohort
(90 separated cells)
Validation cohort
N = 294 whole blood RNA
88 samples and 1784 mapped
miRNA reads
4 target miRNAs tested
3 miRNAs and 2 control
miRNAs included in  nal
analyses
88 samples and 340 miRNAs in
 nal analysis
N = 2 excluded
after quality control
All samples passed
strict QC
1444 miRNAs excluded
(raw reads <1×10–5)
1 target miRNA
excluded
(>25% samples with
undetermined Ct)
Figure 1. Flow diagram showing the two-stage discovery and validation design of the study.
Table 1A. Separated cell discovery cohort
miRNA sequencing discovery cohort
Variable IBD [n = 24] HC [n = 8]
Diagnosis [CD:UC:IBDU] 9:14:1 8
Cell subsets [CD4:CD8:CD14] 23:20:24 7:8:8
Median age, years [range] 34 [18–68] 43 [20–59]
Sex [M:F] 16:8 4:4
CD4: CD4+ T-cells; CD8: CD8+ T-cells; CD14: CD14+ monocytes; CD: 
Crohn’s disease; UC: ulcerative colitis; IBDU: inflammatory bowel disease un-
classified; HC: healthy controls; M: male; F: female. All numbers shown rep-
resent the number of patients.
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a perfect match. miRNAs with raw reads < 1 × 10–5 and samples 
with > 50% of miRNA reads < 5 were excluded from further ana-
lyses. Any cell type mismatches identified from principal compo-
nent analysis were filtered out [n = 2]. A total of 340 miRNAs and 
88 cellular samples were quantile-normalized and further analysed 
for differential expression. R 3.4.4 [R Foundation for Statistical 
Computing] was used for statistical and bioinformatics analysis. 
p-values for differentially expressed proteins were adjusted for 
multiple testing (Benjamini–Hochberg procedure; false discovery 
rate [FDR]].
3.2.  Stage 2: qPCR statistical analysis [relative 
quantification]
Three technical replicates were performed for each assay. Raw Ct 
values were exported for downstream analysis. The expression levels 
of target miRNAs were normalized to two reference genes, miR-
130b-5p and miR-342-3p. 16Relative quantification [i.e. fold change] 
of miRNAs was calculated by the 2−ΔΔCt method.
Means and standard deviations [SD] were generated for each 
sample and for the miRNA target and endogenous controls. An 
SD threshold filter of < 1.0 was used for QC. Target miRNAs in 
Table 1B. Demographics of the quantitative polymerase chain reaction [qPCR] validation cohort
qPCR validation cohort demographics
Variable UC [n = 97] CD [n = 98] Non-IBD [n = 98]
Mean age, years [range] 30 [24–60] 30 [23–35] 26 [23–28]
Gender [M:F] 68:29 47:51 59:39
Centre [UK:Sweden:Norway:Spain] 35:16:41:5 34:22:31:11 20:51:14:13
Smoking status [current:ex:never:unknown] 9:29:57:2 34:15:45:4 17:20:55:6
Non-IBD: Healthy controls   66:32
Montreal location
 E1 23   
 E2 29   
 E3 45   
 L1  37  
 L2  26  
 L3  34  
 L4  1  
Montreal behaviour
 B1 + B1p  81  
 B2  10  
 B3 + B3p  6  
 Not available  1  
CD: Crohn’s disease; UC: ulcerative colitis; IBDU: inflammatory bowel disease unclassified; HC: healthy controls; M: male; F: female. All numbers shown rep-
resent the number of patients.
Table 2. Patient demographics for predicting disease course in inflammatory bowel disease [IBD]
qPCR validation cohort demographics
Variable Escalators [n = 80] Non-escalators [n = 115]
Diagnosis [UC:CD:IBDU] 33:47:0 64:50:1
Median age, years [range] 27 [21–36] 29 [24–34]
Sex [M:F] 46:34 68:47
Centre [UK:Sweden:Norway:Spain] 38:15:23:4 31:23:49:12
Smoking status [current:ex:never:unknown] 20:18:38:4 24:25:64:2
UC classification
 E1 [proctitis] 0 23
 E2 [left-sided colitis] 9 20
 E3 [pancolitis] 24 21
CD classification
 L1 [terminal ileum] 18 18
 L2 [colonic] 11 15
 L3 [ileocolon] 18 16
 L4 [upper gastrointestinal] 0 1
CD behaviour   
 B1, B1p [non-stricturing and non-penetrating, +perianal] 34 46
 B2, B2p [stricturing, +perianal] 8 2
 B3, B3p [penetrating, +perianal] 5 1
 Not available 0 1
Escalation was defined as the need for two or more immunomodulators and/or surgery after initial disease remission. CD: Crohn’s disease; UC: ulcerative colitis; 
IBDU: inflammatory bowel disease unclassified; HC: healthy controls; M: male; F: female. All numbers shown represent the number of patients.
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which > 25% of samples had undetermined Ct values were ex-
cluded from further analyses. There were no samples excluded 
after filtering for QC and three target miRNAs passed QC: miR-
1307-3p, miR-3615 and miR-4792. Fold change was calculated 
using the formula 2−ΔΔCt [equivalent to relative endogenous expres-
sion of target miRNA].
3.3.  Biomarker statistical analyses
Conventional laboratory inflammatory parameters [CRP and al-
bumin], age and sex were included in multivariable models for 
IBD diagnosis and prognosis. CRP and the top miRNAs were 
log10-transformed to approximate a normal distribution for further 
multivariable analysis. The optimal models were then selected by 
performing backward stepwise regression using the lowest Akaike 
information criterion [AIC] values. Leave-one-out [LOO] cross-
validation was used to test the performance of a multi-marker 
diagnostic model.
For the prognostic model, a Cox proportional hazards model 
was derived to assess the contribution of each variable to disease 
outcomes. Thresholds were then identified using receiver operating 
characteristic [ROC] analyses to allow stratification of patients to 
either a benign or an aggressive disease course [requiring treatment 
escalation and/or surgery], and to allow creation of survival curves.
4.  Results
4.1.  Stage 1: miRNA sequencing: Discovery cohort
A total of 90 separated cell samples were selected for sequencing, of 
which 88 samples and 340 miRNAs passed strict QC as described pre-
viously. There were 30 CD4+ T-cell samples, 28 CD8+ T-cell samples and 
30 CD14+ monocyte samples. Principal component analyses demon-
strated distinct clustering based on cell-type [Supplementary Figure 1].
Each cell type was analysed for differential expression in IBD 
compared to controls adjusting for age, sex and batch effects. These 
data are summarized in Table  1A. Three miRNAs differentiated 
IBD from controls in CD4 T-cells: miR-1307-3p [FDR p = 0.01], 
miR-3615 [p = 0.02] and miR-4792 [p = 0.01]. In CD8 T-cells miR-
200b-3p was the only miRNA that was differentially regulated 
in IBD compared to controls [Table  3]. This miRNA was down-
regulated in UC [Supplementary Table 1]. There were no CD14-
specific miRNAs that differentiated UC from controls in this cohort.
Only miR-10b-5p differentiated CD from controls 
[Supplementary Table 2] but no miRNAs differentiated UC from 
CD across all cell subsets.
4.2.  Stage 2: Validating miRNA markers using qPCR
After QC, a total of 294 whole blood RNA samples and three 
target miRNAs were included for further analyses. Table 1B sum-
marizes the demographics of the cohort. There were 97 UC, 98 CD, 
one IBDU and 98 non-IBD controls. In CD, 78% [n = 76] had a B1 
[non-stricturing] phenotype at recruitment. In UC, 24% [n = 23] had 
limited proctitis while 46% [n = 45] had pancolitis at recruitment.
A total of 287 samples passed QC for miR-1307-3p. This miRNA 
was differentially up-regulated in IBD compared to controls (1.55-
fold change [FC], IQR: 1.00–1.87; p = 2.77 × 10–5), consistent with 
the direction of change seen in the sequencing dataset. There was 
no significant difference seen between non-IBD symptomatic con-
trols and healthy controls for miR-1307-3p [p = 0.82]. This miRNA 
was differentially up-regulated in UC [1.69 FC, IQR: 1.01–2.00; 
p = 1.56 × 10–6] and CD [1.42 FC, IQR: 0.84–1.70; p = 0.01] com-
pared to controls and was more highly expressed in UC compared 
to CD [1.19 FC, p = 0.02; Figure 2]. Furthermore, miR-1307-3p was 
more highly expressed with progressive UC extent as defined by the 
Montreal Classification [Kruskal–Wallis p = 0.03] but was not asso-
ciated with CD location or behaviour [p = 0.13].
The other miRNAs, miR-3615 and miR-4792, were differentially 
up-regulated in UC compared to controls [miR-3615: 1.21 FC, IQR: 
0.91–1.48; p = 8.26 × 10–4; miR-4792: 1.91 FC, IQR: 0.81–2.56; 
p = 9.21 × 10–3]. The same miRNAs were overexpressed in pooled 
IBD vs control analyses, but the result failed to reach statistical 
significance.
4.3.  miRNA expression and its association with 
inflammatory activity
Correlation analyses were performed using the top differentially 
expressed miRNAs and conventional blood-based inflammatory 
Table 3. Differential expression of miRNAs in inflammatory bowel disease [IBD] vs healthy controls within separated CD4+, CD8+ and 
CD14+ cells
miRNA Log FC Average relative expression p value FDR p value
CD4 T-cell analyses: IBD vs controls
hsa-miR-4792 6.23 8.54 4.20E-05 0.01
hsa-miR-1307-3p 3.79 11.85 8.24E-05 0.01
hsa-miR-3615 2.69 11.43 2.00E-04 0.02
hsa-miR-320b 2.30 14.05 6.72E-04 0.05
hsa-miR-921 4.98 6.09 7.27E-04 0.05
CD8 T-cell analyses: IBD vs controls
hsa-miR-200b-3p −5.59 3.42 2.79E-05 0.01
hsa-miR-4792 5.26 8.80 2.69E-04 0.05
hsa-miR-30c-5p −1.65 13.05 2.33E-03 0.26
hsa-miR-1246 2.35 10.67 3.73E-03 0.27
hsa-miR-3202 −4.33 4.12 3.95E-03 0.27
CD14 cell analyses: IBD vs controls
hsa-miR-1261 −4.56 4.75 2.96E-03 0.37
hsa-miR-30c-5p −1.63 14.13 0.02 0.37
hsa-miR-576-5p −3.31 6.70 0.01 0.37
hsa-miR-126-5p −3.31 8.01 0.01 0.37
hsa-miR-152-3p −3.34 8.01 0.01 0.37
MicroRNA Profiling in IBD 5
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markers such as hsCRP and albumin [data complete n = 263]. None 
of the miRNAs correlated with conventional blood-based tests such 
as hsCRP or albumin [Table 4].
4.4.  Diagnostic biomarkers in IBD
The top differentially expressed miRNA had modest performance as 
a blood-based diagnostic marker. miR-1307-3p differentiated IBD 
from controls with area under the ROC curve [AUC] of 0.66 (95% 
confidence interval [CI]: 0.59–0.73) and performed on a par with 
hsCRP [AUC 0.67, CI 0.60–0.73; vs miR-1307-3p, p = 0.88] and 
albumin [AUC 0.65, CI 0.59–0.72; vs miR-1307-3p, p = 0.89]. In 
those who were naïve to medical therapy, the diagnostic perform-
ance of miR-1307-3p was similar [0.63, CI: 0.55–0.70, p = 0.55]. 
In CD, miR-1307 had a modest performance in CD [AUC 0.60, CI: 
0.51–0.68]. In UC, miR-1307-3p performed on a par with miR-
3615[p for comparison = 0.10] and miR-4792 [p = 0.09]. A  com-
bined three-miRNA marker provided no added benefit to the 
diagnostic UC model [AUC 0.66, CI: 0.57–0.74]. Figure 3 summar-
izes the diagnostic performance of the miRNAs in IBD and UC com-
pared to controls.
Multivariable logistic regression analysis of predictors of IBD 
was performed on 263 cases [168 IBD, 95 non-IBD] where the 
data for predictors were complete and included miR-1307-3p, al-
bumin and hsCRP. Age (odds ratio [OR]: 1.13, 95% CI: 1.08–1.20, 
p = 8.73 × 10–6), log[hsCRP] [OR: 2.11, CI: 1.26–3.63, p = 5.60 × 10–
3], log[miR-1307] [OR: 6.40, CI: 2.08–20.98, p = 1.56 × 10–3] 
and albumin [OR: 0.92, CI: 0.86–0.99, p = 0.04] were significant 
predictors of IBD. These markers remained significant even after 
adjusting for treatment exposure. An LOO cross-validated diag-
nostic model incorporating these four predictors had an accuracy 
of 0.72 [95% CI: 0.65–0.78] and a positive and negative predictive 
value of 0.73 and 0.67 respectively.
In patients with a negative CRP [hsCRP < 5 mg/L], miR-1307-3p 
had an LOO cross-validated diagnostic accuracy of 0.65 [CI: 0.59–0.70] 
and performed on a par with albumin [accuracy 0.62, CI: 0.56–0.68].
0.0
2.5
5.0
7.5
0.0
2.5
5.0
7.5
Wilcoxon, p = 2.8e-05
R
el
at
iv
e 
ex
pr
es
si
on
 m
iR
-1
30
7
Diagnosis
IBD Non-IBD
0
2
4
6
8
Wilcoxon, p = 0.07
R
el
at
iv
e 
ex
pr
es
si
on
 m
iR
-3
61
5
Diagnosis
IBD Non-IBD
0
3
6
9
Wilcoxon, p = 0.072
R
el
at
iv
e 
ex
pr
es
si
on
 m
iR
-4
79
2
Diagnosis
IBD Non-IBD
0.0
2.5
10.0
12.5
5.0
7.5
R
el
at
iv
e 
ex
pr
es
si
on
 m
iR
-1
30
7
Diagnosisld
CD UCNon-IBD
Diagnosisld
CD UCNon-IBD
Diagnosisld
CD UCNon-IBD
R
el
at
iv
e 
ex
pr
es
si
on
 m
iR
-3
61
5
0
5
10
15
20
25
R
el
at
iv
e 
ex
pr
es
si
on
 m
iR
-4
79
2
0.014
0.82 0.61
0.00920.00083
1.6e-06
Figure 2. Relative expression of miR-1307-3p, miR-3615 and miR-4792 [y-axis] comparing inflammatory bowel disease [IBD] from non-IBD and differentiating 
IBD subtypes (Crohn’s disease [CD] and ulcerative colitis [UC]) from non-IBD. Relative expression is depicted using the 2−ΔΔCq method using miR-130b-5p and 
miR-342-3p as reference genes.
Table 4. Correlation analyses of conventional biomarkers with novel miRNA-based markers
 miRNA Hb WCC Platelet count hsCRP Albumin
miR-1307-3p 0.16 [0.01] 0.00 [0.96] 0.05 [0.40] 0.12 [0.06] −0.04 [0.51]
miR-3615 0.25 [3.08 × 10–5] 0.04 [0.45] 0.15 [0.02] −0.02 [0.75] 0.07 [0.26]
miR-4792 0.23 [4.15 × 10–4] 0.08 [0.24] 0.15 [0.02] 0.07 [0.31] −0.09 [0.19]
Spearman analyses were performed and the data are depicted as rho[p-value]. FC: faecal calprotectin; WCC: white cell count; Hb: haemoglobin; hsCRP: high-
sensitivity C-reactive protein.
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4.5.  miRNAs as predictors of treatment escalation 
in IBD
Prognostic data were available for 195 IBD patients and the demo-
graphics are summarized in Table  2. A  total 80 patients required 
treatment escalation over a median time of 371  days [IQR: 140–
711]. There were no differences in age [p = 0.37] or sex [p = 0.88] 
between the escalator and non-escalator group. A  total of 47 CD 
and 33 UC patients escalated treatment over time defined by the 
need for two or more immunomodulators and/or surgery over time 
after initial disease remission. miR-1307-3p was tested for its prog-
nostic performance. Kaplan–Meier analyses were performed for 189 
patients where data for the predictor had passed QC. miR-1307-3p 
was associated with disease course in IBD (hazard ratio [HR] 1.98, 
IQR: 1.20–3.27; logrank p = 1.80 × 10–3]. Analyses within disease 
sub-types showed that this marker was significantly associated with 
disease course in CD [HR 2.81; IQR: 1.11–3.53, p = 6.50 × 10–4] but 
not UC [p = 0.061].
Similarly, miR-3615 [UC: HR 2.55, IQR: 1.24–5.25, 
p = 3.40 × 10–3; CD: HR 2.01, IQR: 1.07–3.77, p = 0.04] and miR-
4792 [UC: HR 2.29, IQR: 0.93–5.64, p = 0.04; CD: HR 2.42, 
IQR: 1.18–4.97, p = 0.02] predicted disease course in UC and CD 
[Table 5A and Supplementary Figure 2].
4.6.  Multi-marker prognostic models in CD
The prognostic performance of miRNAs was then compared to 
conventional predictors including hsCRP, albumin, age and sex. 
Kaplan–Meier analyses were performed in 167 patients where data 
for the predictors were complete. In CD [n = 84], age < 24  years, 
albumin < 31 g/dL and relative expression of miR-1307-3p > 1.31 
were implicated by modelling [p = 3.00 × 10–8]. At 1 year, the esti-
mated chance of escalation was 21% [CI: 6–34] for patients meeting 
none of the criteria, 21% [CI: 3–36] for patients meeting one cri-
terion and 83% [CI: 58–93] for patients meeting two or more criteria 
[Figure 4 and Table 5B]. Similar prognostic analyses were performed 
in 141 patients [65 CD, 76 UC] in whom miRNA expression data 
for miR-3615 and miR-4792 were available. Including all target 
miRNAs in the multivariate model, miR-1307-3p, albumin and age 
still remained significant predictors in CD and the addition of miR-
4792 and miR-3615 provided no additional benefit to the prognostic 
model. These markers remained significant even after adjusting for 
any treatment exposure at recruitment and smoking status.
4.7.  Multi-marker prognostic models in UC
In UC, similar analyses were performed and included all differen-
tially expressed miRNAs [miR-1307-3p, miR-3615, miR-4792] and 
conventional clinical and biomarker predictors including age, sex, 
hsCRP, albumin and pancolitis subtype, where data for predictors 
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Figure 4. Kaplan–Meier curves of disease course based on blood markers 
in newly diagnosed Crohn’s disease. ‘1 marker’ represents either relative 
miR-1307-3p > 1.31 or albumin < 31 g/dL or age < 24 years. ‘2 or 3 markers’ 
represents a combination of any of the mentioned variables.
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Figure 3. Receiver operator curve [ROC] analyses of miRNAs, high-sensitivity 
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Table 5A. miRNAs as predictors of treatment outcomes in Crohn’s 
disease and ulcerative colitis
Categorical variable HR [IQR] p-value for threshold
Crohn’s disease
miR-1307-3p > 1.29 2.81 [1.11–3.53] 6.50 × 10–4
miR-3615 > 0.89 2.01 [1.07–3.77] 0.04
miR-4792 > 1.11 2.42 [1.18–4.97] 0.02
Ulcerative colitis
miR-1307-3p > 1.43 2.11 [0.98–3.98] 0.06
miR-3615 < 0.95 2.55 [1.24–5.25] 3.40 × 10–3
miR-4792 > 2.22 2.29 [0.93–5.64] 0.04
Categorical thresholds reported for miRNAs are relative expression as cal-
culated by the 2−ΔΔCt method. HR: hazard ratio; IQR: interquartile range.
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were complete [n = 76]. Four markers predicted disease course 
[Figure  5 and Table  5B]: relative miR-3615 expression < 0.95, 
miR-4792 > 2.26, albumin < 39g/dL and extensive colitis [logrank 
p = 6.93 × 10−7]. At 1 year, the estimated chance of escalation was 
6% [CI: 0–17] for patients meeting none of the criteria, 4% [CI:0–
12] for patients meeting one criterion, 31% [CI: 9–48] for patients 
meeting two or more criteria and 90% [CI: 36–98] for patients 
meeting three criterion or more criteria. miR-1307-3p did not pre-
dict outcomes in UC and provided no additional benefit to the UC 
model. These markers remained significant even after adjusting for 
any treatment exposure at recruitment and smoking status.
4.8.  miR-1307 and mRNA integrative network 
analyses
We performed miR-1307-3p target interactions using the miRNet 
online platform.17 A total of 240 genes were targets of these T-cell-
specific miRNAs [Supplementary Table 3] as predicted by miRNet. 
Paired whole blood mRNA expression profiles were available for all 
patients. Of the 240 predicted targets for miR-1307-3p, 63 remained 
significant after FDR correction with 40% [n = 25] of the targets 
negatively correlated with this miRNA. The top-most significant 
negative correlations included ZNF431 [rho −0.27, p = 7.86 × 10–5], 
ZNF841 [−0.33, p = 1.67 × 10–6], LRIG2 [−0.28, p = 4.23 × 10–5] 
and ZNF85 [−0.30, p = 9.51 × 10–5]. Positive correlations included 
MAPK1 [r 0.32, p = 3.21 × 10–6], IL6R [r 0.20, p = 4.55 × 10–3] and 
IL10RB [r 0.20, p = 4.36 × 10–3].
Of the predicted targets for both miR-3615 [n = 39] and miR-
4792 [n = 101], none of the genes remained significant after adjusting 
for multiple testing.
We then performed GO term and KEGG analyses on the gene 
targets using an online platform [Gene Set Enrichment Analysis: 
GSEA].18 Ten GO terms were enriched for miR-1307-3p [Table 
S5]. One of the top miR-1307-3p-specific GO terms in this ana-
lysis included the regulation of T-cell activation and included 
three gene targets: HMGB1 [rho 0.15, p = 4.52 × 10–2], IL6R 
[0.20, p = 4.55 × 10–3] and TMIGD2 [−0.19, p = 9.37 × 10–3]. Only 
one KEGG pathway was enriched and included the regulation of 
adherens junction [KEGG: M638]. This pathway included four gene 
targets from our data, MAPK1, ACTB, ACTG1 and WASF2; these 
were all positively correlated with miR-1307-3p.
5.  Discussion
More recently, there have been rapid advances in our understanding 
of the clinical heterogeneity in IBD. Studies have identified unique 
molecular profiles that represent disease course, behaviour and 
response to therapy.14,15,19–21 With this in mind, there has been im-
mense interest in personalized medicine, to allow enhanced disease 
stratification at diagnosis in order to prevent long-term sequelae and 
improve clinical outcomes. In this study we have identified and val-
idated a novel CD4 T-cell-specific miRNA profile that predicts IBD 
and its disease course over time, at disease inception.
The potential for clinical translation of miRNAs in our study 
lies in their ability to predict treatment escalation in CD and UC. 
Our top differentially expressed and validated miR-1307-3p is able 
to predict treatment escalation in IBD, in particular CD [HR 2.81; 
IQR: 1.11–3.53, p = 6.50 × 10–4]. Combined miRNA-based models 
with blood tests such as albumin further strengthens the perform-
ance of a prognostic model. These miRNAs do not correlate with 
conventional inflammatory markers and may not be driven by the 
inflammatory burden. Our markers have translational relevance as 
they have been validated using RT-qPCR in whole blood, without 
the need to extract immune cells or utilize a new platform that is yet 
to be established in clinical practice. Several studies have investigated 
Table 5B. Multiple categorical logistic regression of predictors of treatment outcomes in crohn’s disease and ulcerative colitis. Categorical 
thresholds reported for miRNAs are relative expression as calculated by the 2^[-ddCt] method. Extensive colitis is defined as E3 as per 
Montreal disease extent classification
Categorical variable HR [IQR] AIC p-value for threshold
Crohn’s disease    
Age < 24 years 2.19 [1.14–4.24] 290.17 0.01
miR1307 > 1.31 2.12 [1.02–4.39] 288.65 0.04
Albumin < 31 g/dL 4.49 [2.08–9.75] 297.70 7.37 × 10–5
Ulcerative colitis
Extensive colitis 3.26 [1.31–8.12] 163.25 0.01
miR-3615 < 0.95 3.63 [1.52–8.66] 164.17 3.60 × 10–3
Albumin < 39g/dL 7.10 [2.69–18.74] 165.50 7.53 × 10–5
miR-4792 > 2.26 4.43 [1.77–11.11] 173.51 1.53 × 10–3
Categorical thresholds reported for miRNAs are relative expression as calculated by the 2−ΔΔCt method. Extensive colitis is defined as E3 as per the Montreal 
disease extent classification. AIC: Akaike information criterion; HR: hazard ratio; IQR: interquartile range.
0.00
0.25
0.50
0.75
1.00
Pr
op
or
ti
on
 w
it
ho
ut
 R
x 
es
ca
la
ti
on
0 250 500 1000750 1250
Time
0 250 500 1000750 1250
Time
p < 0.0001
No marker
1 marker
2 marker
3 or more
Number at risk
18
24
24
14
21
17
9
16
12
6
12
5
2
3
1
0
1
0
10 3 1 0 0 0
Figure 5. Kaplan–Meier curves of disease course based on blood markers 
in newly diagnosed ulcerative colitis. ‘1 marker’ represents either relative 
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disease outcomes in IBD. These have identified unique genetic, gene 
expression, methylation, protein and glycomic profiles that asso-
ciate with an aggressive disease course over time.19–23 Studies have 
used varied criteria to define treatment escalation, including the 
escalation to two or more immunomodulators over time, mucosal 
healing, response to biological agents, and development of fistulizing 
or stricturing complications over time as end points. These are all 
relevant and explore unmet but distinct clinical scenarios. In our 
study, we recruited patients at disease inception who were uniquely 
positioned to investigate treatment escalations over time as defined 
by transcriptome and protein studies.14,15,20,23 Our study provides 
another level of molecular depth in these patients by defining cell-
specific miRNA markers that associate with disease course. Future 
studies integrating these multi-omic markers may provide mechan-
istic insights into aggressive clinical course and provide future drug 
targets. In CD, activated T-cells represent a key cell type within a 
unique cellular component [GIMATS] that when present in dis-
ease, has been shown to associate with anti-tumour necrosis factor 
drug resistance.24 Our findings may be of relevance in the context 
of drug response, but this remains to be explored. Future studies 
incorporating these signals in treatment response/non-response 
would be of interest. Recently, there have been studies exploring the 
role of miRNA-based biomarkers as tools for disease monitoring 
and treatment response in IBD and other immune-mediated diseases. 
Circulating miR-146b-5p AUC [0.869, CI: 0.764–0.940] has been 
shown to better reflect mucosal inflammation in IBD compared to 
CRP [0.680, CI: 0.554–0.790, p for comparison = 0.0043]. Mucosal 
miRNA profiles generated in acute severe colitis patients identified a 
panel of nine miRNAs and five clinical factors that can differentiate 
responders vs non-responders with steroids [AUC 0.91], infliximab 
[AUC 0.82] and cyclosporine [AUC 0.79].25 In rheumatoid arthritis, 
circulating levels of three miRNAs, miR-155-5p, miR-146a-5p and 
miR-132-3p, predict response to methotrexate, all with similar AUC 
[0.72–0.76].26
Published miRNA studies in peripheral blood of IBD patients 
are limited by cellular heterogeneity within the biological sam-
ples analysed.5 In our study, we have profiled miRNAs in cell-
specific peripheral blood cells and validated these signals in whole 
blood. All three validated miRNAs in whole blood show signals 
in CD4 T-cells and are up-regulated in IBD. Our methodology of 
utilizing RNA sequencing on separated cells has identified novel, 
yet undiscovered IBD-specific miRNAs. From GO term analysis, 
miR-1307-3p appears to target genes that control several cellular 
pathways, in particular regulation of T-cell activation. Correlation 
analysis also reveals positive correlations with pro-inflammatory 
gene targets such as IL6R and MAPK1, particularly relevant in 
chronic inflammatory disorders such as IBD. KEGG analysis reveals 
that this miRNA and its targets may also be involved in regulating 
intestinal barrier function, possibly through MAPK signalling. 
The exact role of miR-1307-3p in disease pathogenesis and T-cell 
function remain to be explored. Much of the literature on miR-
1307-3p biology is in the field of cancer. In colon adenocarcinoma, 
miR-1307-3p targets isthmin1 [ISM1], inhibiting Wnt3a/β-catenin 
signalling and cell proliferation and promoting cell apoptosis.27 
Germline variation in pre-miR-1307-3p [rs7911488] was signifi-
cantly associated with efficacy to capecitabine-based chemotherapy 
in colon cancer; rs7911488 C-allelic pre-miR-1307 was associated 
with poor drug response through the attenuation of mature miR-
1307 levels and up-regulation of its target TYMS.28 Conversely, 
miR-1307-3p appears to be detrimental in hepatocellular car-
cinoma and breast cancer, predicting poor clinical outcomes if 
over-expressed.29,30 Within our prognostication data, there is diver-
gent expression seen for miR-3615 in IBD subtypes amongst escal-
ators and non-escalators. This warrants further exploration. Given 
that miRNAs regulate gene expression, their own expression may 
vary based on disease subtype and severity. An example includes 
the divergent influence of miR-21 in murine models of acute DSS-
induced colitis vs chronic TNBS-induced colitis.1 Studies are needed 
to investigate their mechanistic role in disease course and severity. 
Furthermore, studies exploring their dynamic differential regulation 
of the miRNAs over time are also needed.
Our findings provide an enriched resource for future studies to 
evaluate the function of this resource in IBD.
There are certain methodological considerations in our study 
that are worthy of discussion. Our study design, identifying and 
validating differentially expressed miRNAs in IBD compared to 
controls, may not capture all prognostic miRNAs relevant in IBD. 
However, this would require a much larger multi-centre pool of 
purified immune cell subsets in a treatment-naïve IBD cohort with 
follow-up data, beyond the scope of this study. Patients with IBD 
may have different cellular proportions compared to controls and 
this may influence cell-specific results. However, there was no cor-
relation seen between the miRNAs and white blood cell count. 
Treatment may be escalated in response to blood markers, thereby 
confounding our findings of routine clinical markers predicting es-
calation. This is likely to explain the over-representation of albumin 
in most prognostic models. As decisions on treatment escalations 
are based on clinical tests such as CRP and albumin, it is note-
worthy that the miRNA markers still remain significant predictors 
in IBD. Decisions regarding treatment escalation may vary across 
centres but it is important to highlight that in our study, all centres 
utilized a step-up approach when tailoring therapy. The major 
strengths of the study include a two-stage prospective study design 
including target validation, cell-specific profiling and a multi-centre 
recruitment of patients at disease inception. Erythropoietically de-
rived miR486-5p and miR-451 reads can often be over-represented 
in small RNA sequencing studies that profile whole blood, resulting 
in inaccurate quantification and detectability of low-abundance sig-
nals that may in fact be relevant in disease pathogenesis.31 We there-
fore used RT-qPCR to validate our findings in whole blood. Studies 
are now developing novel hybridization methods to deplete these 
miRNAs to allow detection of low-abundance miRNAs in whole 
blood.31
Our work adds to the valuable literature defining the epigenome 
in IBD, in particular cell-specific miRNAs. These data will allow 
future studies to explore the epigenetic alterations that associate 
with disease onset and outcomes and pave the way potentially for 
miRNA-based therapeutics.
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